5 November 2024NewsAmericasOlga Zimmerman Director Intellectual Property Caribou Biosciences, Matthew Gordon Vice President Legal Myriad Genetics Inc, Susan Krumplitsch Partner DLA Piper, William Mulholland Partner DLA Piper, Graham Cole Director Intellectual Property Office of Technology Licensing City of Hope
WATCH: Navigating enablement and written description requirement standards in the USPTO
On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 January 2026 The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent.